Cardiotensin for patients with intractable angina pectoris and acute cardiac dysfunction

Abstract

Objective To explore the clinical efficacy of cardiotensin for patients with acute cardiac dysfunction and intractable angina pectoris. Methods In a random lottery pattern, 60 patients with intractable angina pectoris and acute cardiac dysfunction treated at our hospital from May, 2015 to May, 2016 were selected and divided into an observation group and a control group according to different hospitalization time and their voluntary admission. The control group were treated with nitroglycerin and the observation group with cardiotensin. The total effective rate, incidence of adverse reactions, seizure frequency, duration, myocardial ischemia total load grade, length of hospital stay, and indicator changes were compared between these two groups. Results The total effective rate was higher in the observation group than in the control group (90.00% vs. 66.67%). The incidence of adverse reactions was lower in the observation group than in the control group (16.67% vs. 40.00%). The acute angina pectoris attack frequency, duration, hospitalization time, and other treatment conditions were better in the observation group than in the control group. The LVEF, BNP, myocardial ischemia score, and urine volume were all better in the observation group than in the control group, with statistical differences (all P< 0.05). Conclusion Cardiotensin for patients with intractable angina pectoris and acute cardiac decompensation not only effectively enhances the treatment efficacy and improve the cardiac function, but also alleviates symptoms, shortens the time of angina pectoris attack frequency, and has few adverse reactions, short hospitalization time, high safety, and good clinical value, so it is worth being clinically generalized. Key words: Cardiotensin; Acute cardiac dysfunction and intractable angina pectoris; Clinical efficacy